新华制药(000756.SZ)：子公司获得沙格列汀二甲双胍缓释片药品注册证书

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the drug registration certificate for Saxagliptin and Metformin Extended-Release Tablets (Ⅰ) and (Ⅲ) from the National Medical Products Administration [1] Company Summary - The newly approved medication is intended for adult patients with type 2 diabetes who are suitable for treatment with Saxagliptin and Metformin, aimed at improving blood glucose control [1] - The product is not indicated for patients with type 1 diabetes or diabetic ketoacidosis [1]